CDAC Platform Asset(s)
Undisclosed B-Cell Malignancies
Discovery / Preclinical / Early ClinicalActive R&D
Key Facts
Indication
Undisclosed B-Cell Malignancies
Phase
Discovery / Preclinical / Early Clinical
Status
Active R&D
Company
About BeOne Medicines
BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.
View full company profile